| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10004349 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10015578 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10006128 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10016062 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10028498 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10028499 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10021267 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10028500 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10038364 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
| TVIS10040827 | HBV | ENSG00000171094.18 | protein_coding | ALK | Yes | No | 238 | B6D4Y2 Q9UM73 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ALK |
|---|---|
| DrugBank ID | DB09063 |
| Drug Name | Ceritinib |
| Target ID | BE0000359 |
| UniProt ID | Q9UM73 |
| Regulation Type | antagonist |
| PubMed IDs | 17185414; 23742252 |
| Citations | Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, Wan Y, Ding P, Liu Y, Sun F, Schultz PG, Gray NS, Warmuth M: Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5. Epub 2006 Dec 21.@@Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY: Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26. |
| Groups | Approved |
| Direct Classification | Phenylpiperidines |
| SMILES | CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL2403108 |
